Viatris
Viatris Inc is a global healthcare company formed through the combination of Mylan and Upjohn, a former division of Pfizer. The company's business operations center on the development, manufacturing, and distribution of prescription branded medicines, generic drugs, and complex biosimilars. Revenue is primarily driven by sales of established pharmaceuticals targeting cardiovascular health, central nervous system disorders, infectious diseases, and immunology. Its principal end markets encompass retail pharmacies, hospital networks, government health agencies, and patients across more than 165 countries. The company's portfolio features recognized global brands such as Lipitor, Viagra, Norvasc, Lyrica, and EpiPen. Viatris ranks as one of the largest pharmaceutical suppliers of generic and legacy branded therapeutics in the world. The company is headquartered in Canonsburg, Pennsylvania, United States, and its stock is listed on Nasdaq.
35 of the funds FundTelligence covers report a position in Viatris.
- Legal name
- Viatris Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 35
Funds holding Viatris
- DWS Invest CROCI Sectors Plus — DWS · 3.29 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI US — DWS · 2.4 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.47 % (full portfolio disclosed, October 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 1.09 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI World Value — DWS · 1.0 % (full portfolio disclosed, June 2026)
- Alfred Berg Short Global IG Corporate Bond Fund — Alfred Berg · 0.91 % (full portfolio disclosed, June 2026)
- Cicero Offensiv Hållbar — Cicero Fonder · 0.75 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Corporate Bond — Schroders · 0.67 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 35 funds holding it.